NASDAQ:LRMR Larimar Therapeutics Q2 2025 Earnings Report $3.21 -0.11 (-3.31%) Closing price 04:00 PM EasternExtended Trading$3.22 +0.01 (+0.31%) As of 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Larimar Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.49Beat/MissN/AOne Year Ago EPSN/ALarimar Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALarimar Therapeutics Announcement DetailsQuarterQ2 2025Date8/6/2025TimeBefore Market OpensConference Call DateWednesday, August 6, 2025Conference Call Time7:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Larimar Therapeutics Earnings HeadlinesLarimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's AtaxiaJuly 8, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Larimar Therapeutics (LRMR)June 24, 2025 | theglobeandmail.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.July 18 at 2:00 AM | Brownstone Research (Ad)Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia ProgramJune 23, 2025 | globenewswire.comLarimar Therapeutics to Host Conference Call on Regulatory Updates for Nomlabofusp Clinical Development ProgramJune 22, 2025 | nasdaq.comLarimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s AtaxiaJune 20, 2025 | finance.yahoo.comSee More Larimar Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Larimar Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Larimar Therapeutics and other key companies, straight to your email. Email Address About Larimar TherapeuticsLarimar Therapeutics (NASDAQ:LRMR) is a clinical-stage biotechnology company specializing in the development of next-generation immunotherapies using engineered exosomes as delivery vehicles. The company’s proprietary ExoIL-12 platform is designed to encapsulate and deliver interleukin-12 directly to the tumor microenvironment, aiming to enhance anti-tumor immune responses while minimizing systemic toxicity. In addition to its lead candidate, exoIL-12, Larimar is advancing ExoASO-STAT6, an exosome-encapsulated antisense oligonucleotide intended to reprogram immunosuppressive cells within solid tumors. By leveraging a bioengineered exosome delivery system, Larimar aims to overcome longstanding challenges associated with cytokine therapy and oligonucleotide delivery. The company’s approach combines targeted biodistribution with controlled payload release, potentially enabling higher therapeutic doses and improved safety profiles. Larimar’s preclinical programs have demonstrated robust tumor infiltration and immune activation, supporting its ongoing phase 1 clinical trials for patients with advanced or metastatic solid tumors. Founded in 2016 as a spin-out from research at the Massachusetts Institute of Technology, Larimar Therapeutics is headquartered in Cambridge, Massachusetts, with research and development operations in the Boston area. Under the leadership of President and CEO Glen Allcorn, the company has established collaborations with academic institutions and contract research organizations to advance its manufacturing and clinical development capabilities. Larimar continues to explore global partnerships to expand its pipeline and bring novel exosome-based therapies to patients in need.Written by Jeffrey Neal JohnsonView Larimar Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025)General Motors (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
